List of Tables
    Table 1. Durvalumab CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Durvalumab Market Trends
    Table 3. Durvalumab Market Drivers
    Table 4. Durvalumab Market Challenges
    Table 5. Durvalumab Market Restraints
    Table 6. Global Durvalumab Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Durvalumab Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Durvalumab Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Durvalumab Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Durvalumab Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Durvalumab Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Durvalumab Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Durvalumab Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Durvalumab Sales Share by Manufacturer, 2017-2022
    Table 15. Global Durvalumab Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Durvalumab Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Durvalumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Durvalumab as of 2021)
    Table 18. Top Players of Durvalumab in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Durvalumab Product Type
    Table 20. Date of International Manufacturers Enter into Durvalumab Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Durvalumab Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Durvalumab Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Durvalumab Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Durvalumab Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Durvalumab Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Durvalumab Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Durvalumab Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Durvalumab Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Durvalumab Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Durvalumab Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Durvalumab Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Durvalumab Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Durvalumab Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Durvalumab Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Durvalumab Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Durvalumab Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Durvalumab Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Durvalumab Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Durvalumab Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Durvalumab Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Medimmune (AstraZeneca) Corporation Information
    Table 43. Medimmune (AstraZeneca) Description and Business Overview
    Table 44. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Medimmune (AstraZeneca) Durvalumab Product
    Table 46. Medimmune (AstraZeneca) Recent Development
    Table 47. Key Raw Materials Lists
    Table 48. Raw Materials Key Suppliers Lists
    Table 49. Durvalumab Customers List
    Table 50. Durvalumab Distributors List
    Table 51. Research Programs/Design for This Report
    Table 52. Key Data Information from Secondary Sources
    Table 53. Key Data Information from Primary Sources
List of Figures
    Figure 1. Durvalumab Product Picture
    Figure 2. Global Durvalumab Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Durvalumab Market Size 2017-2028 (US$ Million)
    Figure 4. Global Durvalumab Sales 2017-2028 (K Pcs)
    Figure 5. United States Durvalumab Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Durvalumab Market Size 2017-2028 (US$ Million)
    Figure 7. United States Durvalumab Sales 2017-2028 (K Pcs)
    Figure 8. United States Durvalumab Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Durvalumab Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Durvalumab Report Years Considered
    Figure 11. Product Picture of 2.4mL Injection
    Figure 12. Product Picture of 10mL Injection
    Figure 13. Global Durvalumab Market Share by Type in 2022 & 2028
    Figure 14. Global Durvalumab Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 15. Global Durvalumab Sales Market Share in Value by Type (2017-2028)
    Figure 16. Global Durvalumab Sales by Type (2017-2028) & (K Pcs)
    Figure 17. Global Durvalumab Sales Market Share in Volume by Type (2017-2028)
    Figure 18. Global Durvalumab Price by Type (2017-2028) & (USD/Pcs)
    Figure 19. United States Durvalumab Market Share by Type in 2022 & 2028
    Figure 20. United States Durvalumab Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 21. United States Durvalumab Sales Market Share in Value by Type (2017-2028)
    Figure 22. United States Durvalumab Sales by Type (2017-2028) & (K Pcs)
    Figure 23. United States Durvalumab Sales Market Share in Volume by Type (2017-2028)
    Figure 24. United States Durvalumab Price by Type (2017-2028) & (USD/Pcs)
    Figure 25. Product Picture of Locally Advanced Urothelial Carcinoma
    Figure 26. Product Picture of Metastatic Urothelial Carcinoma
    Figure 27. Product Picture of Other
    Figure 28. Global Durvalumab Market Share by Application in 2022 & 2028
    Figure 29. Global Durvalumab Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 30. Global Durvalumab Sales Market Share in Value by Application (2017-2028)
    Figure 31. Global Durvalumab Sales by Application (2017-2028) & (K Pcs)
    Figure 32. Global Durvalumab Sales Market Share in Volume by Application (2017-2028)
    Figure 33. Global Durvalumab Price by Application (2017-2028) & (USD/Pcs)
    Figure 34. United States Durvalumab Market Share by Application in 2022 & 2028
    Figure 35. United States Durvalumab Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 36. United States Durvalumab Sales Market Share in Value by Application (2017-2028)
    Figure 37. United States Durvalumab Sales by Application (2017-2028) & (K Pcs)
    Figure 38. United States Durvalumab Sales Market Share in Volume by Application (2017-2028)
    Figure 39. United States Durvalumab Price by Application (2017-2028) & (USD/Pcs)
    Figure 40. North America Durvalumab Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 41. North America Durvalumab Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 42. U.S. Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Canada Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Europe Durvalumab Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 45. Europe Durvalumab Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 46. Germany Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. France Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. U.K. Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Italy Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Russia Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Asia-Pacific Durvalumab Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 52. Asia-Pacific Durvalumab Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 53. China Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Japan Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. South Korea Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. India Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Australia Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Taiwan Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Indonesia Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Thailand Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Malaysia Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Philippines Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Latin America Durvalumab Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 64. Latin America Durvalumab Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 65. Mexico Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Brazil Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Argentina Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Middle East & Africa Durvalumab Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 69. Middle East & Africa Durvalumab Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Turkey Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Saudi Arabia Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. U.A.E Durvalumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Durvalumab Value Chain
    Figure 74. Durvalumab Production Process
    Figure 75. Channels of Distribution
    Figure 76. Distributors Profiles
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed